GlassScriptPhysician profile
Hasmukh Jariwala
NPI 1699882738
$619.73
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $288 · 2020: $85.18 · 2021: $163 · 2022: $83.32.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $199.27 | 2019-2022 | |
| Pfizer INC. | $158.48 | 2019-2022 | |
| Glaxosmithkline, LLC. | $77.60 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $34.26 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.86 | 2019-2021 | |
| Sanofi Pasteur INC. | $30.51 | 2019 | |
| Novo Nordisk INC | $18.52 | 2021 | |
| Abbvie INC. | $16.84 | 2021 | |
| Lilly USA, LLC | $13.78 | 2022 | |
| Amgen INC. | $13.67 | 2020 | |
| Mdd US Operations, LLC | $11.54 | 2019 | |
| Amarin Pharma, INC. | $11.40 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hasmukh Jariwala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.